French medicine regulator bans two cannabinoid derivatives after reported side effects

These new cannabinoids mimic the effects of THC, the main psychoactive component of cannabis, but with greater severity and intensity than the traditional recreational substance, the ANSM said. The cannabinoid concentration is often “high and unknown to the consumer,” and the composition printed on...

Full description

Saved in:
Bibliographic Details
Published in:BMJ (Online) 2024-06, Vol.385, p.q1249
Main Author: Casassus, Barbara
Format: Article
Language:English
Subjects:
Bans
Cannabidiol
Cannabinoids - adverse effects
Clinical trials
Dronabinol - adverse effects
Dronabinol - analogs & derivatives
Drug and Narcotic Control - legislation & jurisprudence
Epilepsy
France
Humans
Marijuana
Multiple sclerosis
Myocardial infarction
Neuralgia
Neurological diseases
News
Renal failure
Synthetic products
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:These new cannabinoids mimic the effects of THC, the main psychoactive component of cannabis, but with greater severity and intensity than the traditional recreational substance, the ANSM said. The cannabinoid concentration is often “high and unknown to the consumer,” and the composition printed on the packaging can be flawed, it added.
ISSN:1756-1833
1756-1833
DOI:10.1136/bmj.q1249